| Literature DB >> 30410712 |
Abbas Zakeri1, Mohammad Amin Jadidi Kouhbanani1, Nasrin Beheshtkhoo1, Vahid Beigi2, Seyyed Mojtaba Mousavi1,3, Seyyed Ali Reza Hashemi1,3, Ayoob Karimi Zade1, Ali Mohammad Amani1,2, Amir Savardashtaki4, Esmail Mirzaei1, Sara Jahandideh5, Ahmad Movahedpour4.
Abstract
The meaning of gene therapy is the delivery of DNA or RNA to cells for the treatment or prevention of genetic disorders. The success rate of gene therapy depends on the progression and safe gene delivery system. The vectors available for gene therapy are divided into viral and non-viral systems. Viral vectors cause higher transmission efficiency and long gene expression, but they have major problems, such as immunogenicity, carcinogenicity, the inability to transfer large size genes and high costs. Non-viral gene transfer vectors have attracted more attention because they exhibit less toxicity and the ability to transfer large size genes. However, the clinical application of non-viral methods still faces some limitations, including low transmission efficiency and poor gene expression. In recent years, numerous methods and gene-carriers have been developed to improve gene transfer efficiency. The use of Polyethylenimine (PEI) based transfer of collaboration may create a new way of treating diseases and the combination of chemotherapy and gene therapy. The purpose of this paper is to introduce the PEI as an appropriate vector for the effective gene delivery.Entities:
Keywords: Polyethylenimine; co-delivery; nanocarrier
Year: 2018 PMID: 30410712 PMCID: PMC6171788 DOI: 10.1080/20022727.2018.1488497
Source DB: PubMed Journal: Nano Rev Exp ISSN: 2002-2727
Figure 1.Classification of cationic polymers [14].
Figure 2.PEI Structure [15].
Figure 3.Schematic of BPEI copolymers preparation [20].
Figure 4.Schematic of the confined impinging jet (CIJ) device used to fabricate polyelectrolyte complex nanoparticles under rapid mixing conditions. (Streams are loaded independently with PEI/DNA plasmid and PEI/DNA nanoparticles, and are placed in a small compartment prior to collection [29].).
Selected evidence on the therapeutic appeal of poly (ethylenimine) for co-delivery.
| Vector | PEI used | Co delivery | Disease model | Properties Therapeutic effects | Ref |
|---|---|---|---|---|---|
| hybrid micelles (PCL-PEI) and (PCL-PEG) | PEI2k | Dex or siRNA | Rheumatoid arthritis | Reduce inflammation, without damaging renal or liver function. | [ |
| cationic pullulan-g-desoxycholic acid-g-PEI | lMbPEI(1kDa) | DOX and P53 | MCF-7 cells | Improving antitumor efficacy and systemic toxicity | [ |
| poly(EI-co-DCA) copolymers | Linear polyethyleneimine (PEI 423) | Drug demethylcantharate and Akt1 shRNA | (SMMC7721, MCF-7 and A549 cells) | In the present form significantly and synergistically suppress the growth and metastasis of three human cancer cells (SMMC-7721, MCF-7 and A549 cells) | [81] |
| (FA)-decorated PEG-b-(PCL-g-PEI)-b-PCL triblock copolymers | PEI800 | siRNA and doxorubicin (DOX) | Breast cancer cells | These results proof that PECL3 micelles could co-deliver siRNA and drug to inhibit MDR tumor growth. thus can efficiently reverse MDR cancer and kill the cancer cells | [ |
| HA/PEI-PLGA nanoparticles | Linear PEI with the terminal hydroxyl group | Doxorubicin (DOX) and miR-542-3p | TNBCMCF-7 and MDA-MB-231 cells | These nanoparticles have the potential to co-deliver chemotherapeutic agents and tumor suppressive miRNAs in combinatorial TNBC therapy and increased both drug uptake and cytotoxicity in MDA-MB-231 cells | [ |
| PEI-hyd-DOX | High molecular weight of 5000 (PEI5k) | pGL-3 plasmid and DOX | HeLa and 293T cells | Proven to be bio-controllably released inside the cells with an enhanced drug efficacy. applicable for the combination of chemotherapy and gene therapy | [ |
| PEI and PCL graft copolymer | LMw-PEI | Dox and p53-pDNA | HepG2, Hela and glial tumor | Great potential of the copolymer as an effective platform which provides a stronger cytotoxic effect via higher cellular transfection and simultaneous drug and gene delivery against aggressive cancers | [ |
| Two amphiphilic diblock copolymers, (PCL-PEI) and (PCL-PEG) | Branched poly-(ethyleneimine) | MicroRNA-34a and Vismodegib | B16F10-CD44+ cells | Candidate delivery vehicle associated with excellent delivery performance and minimal toxicity and great potential in cancer therapy | [83] |
Abbreviations: PCL: polycaprolactone, PEI: polyethylenimine; PEG: polyethyleneglycol; Dex: dexamethasone; siRNA: small-interfering RNA; lMbPEI: low-molecular weight branched polyethylenimine; DOX: doxorubicin poly(EI, co-DCA) poly(ethylenimine-co-demethylcantharate); FA: folic acid; TNBC: triple negative breast cancer, HeLa: Human cervix carcinoma cells, 293T: human embryonic kidney transformed 293 cells, -pDNA: plasmid DNA, HepG2: human hepatoma cell line, PLGA: poly (lactic-co-glycolic) acid.
Figure 5.Cell viability and gel electrophoresis assays of different nanocomplexes [77].
Abbreviations: PEI: polyethyleneimine, QD: quantum dot, N/P: nitrogen to phosphate.
Figure 6.Chemical structures of the degradable cationic polymers [80].
Abbreviations:PHP: Poly(4-hydroxy-L-proline ester); PAGA: Poly(γ-(4-aminobutyl)-L-glycolic acid); SS-PAEI: Reducible poly(amido ethylenimine); SS-PAA: series of linear bioreducible poly(amido amine); PPA: poly(phosphoramidates); PPZ: poly(phosphazenes); p(DMAEMA): poly(dimethylaminoethyl methacrylate); IPEMA: 3-imidazol-1-yl-propionic acid ester of hydroxyethyl methacrylate; PPE: poly(phosphoesters); pHPMA: poly(N-2-hydroxypropyl methacrylamide); DMAE: dimethylaminoethyl; MPPM: 1-methyl-2-piperidine methanol; DEAE: N,N-diethylaminoethanol; DTBP: dimethyl 3,3ʹ-dithiobispropionimidate; PEI: poly(ethylene imine); PEG: poly(ethylene glycol); PLL: Poly(L-lysine); DSP: dithiobis(succinimidylpropionate).